<p>Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD</p>

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD

<p>Gilead Sciences has been one of biopharma's worst performers,&nbsp;and demand for its&nbsp;hepatitis C drugs&nbsp;has yet to bottom. Can its R&amp;D program jump&nbsp;start investor&nbsp;optimism?&nbsp;Stocks: GILD</p>

Healthcare: Should You Stick With Gilead Sciences?

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Should You Stick With Gilead Sciences?

Sign up to save your podcasts

Healthcare: Should You Stick With Gilead Sciences?

Healthcare: Should You Stick With Gilead Sciences?